deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT01492725

Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial (EXTEND-IA)

A Randomized Controlled Trial of Intra-arterial Reperfusion Therapy After Standard Dose Intravenous t-PA Within 4.5 Hours of Stroke Onset Utilizing Dual Target Imaging Selection.

Sponsor: Neuroscience Trials Australia

Conditions Ischemic Stroke
Interventions Intra-arterial Clot Retrieval with Solitaire device intravenous tissue plasminogen activator (tPA)
Updated 5 times since 2017 Last updated: Apr 20, 2015 Started: Jun 30, 2012 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

On DSMB advice, trial recruitment has been halted for efficacy. F/U continues

Other Ischemic Stroke trials with similar outcome

Browse all Ischemic Stroke trials

This PHASE2 trial investigates Ischemic Stroke and is currently terminated or withdrawn. Neuroscience Trials Australia leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Neuroscience Trials Australia
Data source: Neuroscience Trials Australia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations